A study conducted in a cohort of 50 Italian MS patients, including 22 responders and 28 non-responders to interferon-beta (IFN-beta) therapy, aimed to assess ITGA4 expression in both groups. The gene discussed is ITGA4; the disease is myeloid sarcoma.